Inhibikase Therapeutics logo
Inhibikase Therapeutics IKT
$ 3.2 0.0%

Quarterly report 2024-Q3
added 11-14-2024

report update icon

Inhibikase Therapeutics Interest Expense 2011-2024 | IKT

Annual Interest Expense Inhibikase Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.06 M 74.5 K -19.9 K 29.4 K - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.06 M -19.9 K 286 K

Quarterly Interest Expense Inhibikase Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
49.4 K 90.9 K 133 K - 174 K 424 K 237 K - 18.5 K 5 -5 - 157 7.81 K 11.8 K - 6.89 K 7.95 K 7.42 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
424 K -5 77.9 K